Equillium Inc (EQ)
1.67
+0.11
(+7.05%)
USD |
NASDAQ |
May 03, 16:00
1.69
+0.02
(+1.20%)
Pre-Market: 20:00
Equillium Cash from Operations (TTM): -21.78M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -21.78M |
September 30, 2023 | 11.61M |
June 30, 2023 | 0.45M |
March 31, 2023 | -4.594M |
December 31, 2022 | -8.733M |
September 30, 2022 | -46.59M |
June 30, 2022 | -40.54M |
March 31, 2022 | -36.27M |
December 31, 2021 | -32.08M |
September 30, 2021 | -30.20M |
June 30, 2021 | -28.11M |
Date | Value |
---|---|
March 31, 2021 | -26.20M |
December 31, 2020 | -24.62M |
September 30, 2020 | -25.40M |
June 30, 2020 | -25.18M |
March 31, 2020 | -24.86M |
December 31, 2019 | -22.95M |
September 30, 2019 | -17.74M |
June 30, 2019 | -14.69M |
March 31, 2019 | -11.10M |
December 31, 2018 | -7.526M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-46.59M
Minimum
Sep 2022
11.61M
Maximum
Sep 2023
-22.03M
Average
-24.86M
Median
Mar 2020
Cash from Operations (TTM) Benchmarks
Janux Therapeutics Inc | -50.58M |
Mersana Therapeutics Inc | -168.88M |
Vera Therapeutics Inc | -92.18M |
Jasper Therapeutics Inc | -52.07M |
PepGen Inc | -69.00M |